Responses
Section 1: Introductory statements and governance
1ISG-005 A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous non-small-cell lung cancer in second line in a healthcare setting
Compose a Response to This Article
Other responses
No responses have been published for this article.